The use of ofatumumab in the treatment of B-cell malignancies

Soe, Zar Ni; Allsup, David

Abstract

Ofatumumab has been extensively studied in the treatment of B-cell malignancies. Currently, it has been approved for the treatment of chronic lymphocytic leukemia in a number of different situations. However, there is still no compelling evidence confirming the superiority of ofatumumab over rituximab in vivo. In this article, we summarize the currently available clinical data supporting the use of ofatumumab in the treatment of B-cell malignancies. The clinical studies were searched from clinicaltrials.gov with the key words ofatumumab, HuMax-CD20. Out of 115 trials available, studies for B-cell malignancies were selected, followed by selection of completed studies with results and active ongoing studies. The results from completed studies were thoroughly analyzed and active ongoing studies were listed in tables.

Citation

Soe, Z. N., & Allsup, D. (2017). The use of ofatumumab in the treatment of B-cell malignancies. Future oncology, 13(29), 2611-2628. https://doi.org/10.2217/fon-2017-0275

• Journal Article Type: Article
• Acceptance Date: Aug 4, 2017
• Online Publication Date: Aug 29, 2017
• Publication Date: 2017-12
• Deposit Date: Mar 22, 2018
• Journal: Future Oncology
• Print ISSN: 1479-6694
• Electronic ISSN: 1744-8301
• Publisher: Future Medicine
• Peer Reviewed: Peer Reviewed
• Volume: 13
• Issue: 29
• Pages: 2611-2628
• DOI: https://doi.org/10.2217/fon-2017-0275
• Keywords: B-cell malignancies; Chemotherapy; Leukemia
• Public URL: https://hull-repository.worktribe.com/output/752040
• Publisher URL: https://www.futuremedicine.com/doi/full/10.2217/fon-2017-0275